Abbott Laboratories dividend yield – Abbott Laboratories Increases Quarterly Dividend by 7.8% to $0.55/Share
December 16, 2023
🌥️Trending News
It operates in diagnostics, medical devices, nutritionals, branded generic pharmaceuticals, and animal health products. Abbott ($NYSE:ABT) is one of the world’s leading manufacturers of medical devices for diagnostics and monitoring, with products ranging from glucose meters to CT scanners.
Dividends – Abbott Laboratories dividend yield
Analysts predict that the dividend yields of Abbott Laboratories from 2021 to 2023 will be 1.9%, 1.61%, and 1.54%, respectively, with an average dividend yield of 1.68%. This makes it a profitable investment choice for investors looking for a steady dividend payout. With this announcement, Abbott Laboratories has once again reaffirmed its commitment to providing consistent and reliable dividends to its shareholders.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Abbott Laboratories. More…
| Total Revenues | Net Income | Net Margin |
| 39.96k | 5.16k | 12.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Abbott Laboratories. More…
| Operations | Investing | Financing |
| 7.45k | -1.74k | -7.64k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Abbott Laboratories. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 73.35k | 35.95k | 21.42 |
Key Ratios Snapshot
Some of the financial key ratios for Abbott Laboratories are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 7.4% | 11.6% | 16.3% |
| FCF Margin | ROE | ROA |
| 13.7% | 11.0% | 5.6% |
Analysis – Abbott Laboratories Intrinsic Value
At GoodWhale, we recently completed an analysis of ABBOTT LABORATORIES, a major healthcare and pharmaceutical company. Through our proprietary Valuation Line, we found that the fair value of ABBOTT LABORATORIES stock is approximately $124.3. However, the current market price of ABBOTT LABORATORIES stock is only $107.3 – a 13.7% discount from its fair value. This indicates that ABBOTT LABORATORIES stock is currently undervalued and could offer investors the opportunity to engage in a good buy at its current price. More…
Peers
Abbott Laboratories is a large, publicly traded company that manufactures and sells medical products, including diagnostics, devices, and branded generic pharmaceuticals. The company has a diversified product portfolio and a strong presence in multiple global markets. However, Abbott Laboratories faces stiff competition from other large medical companies, such as OraSure Technologies Inc, Quidel Corp, and Lucira Health Inc.
– OraSure Technologies Inc ($NASDAQ:OSUR)
OraSure Technologies Inc is a leader in developing, manufacturing, and marketing oral fluid diagnostic products. The company’s products are used for the detection of antibodies to HIV and HCV, as well as for the detection of drugs of abuse. OraSure’s products are sold in over 60 countries worldwide. The company has a market cap of 283.94M as of 2022, a Return on Equity of -8.39%.
OraSure Technologies is dedicated to improving global health by developing and delivering innovative point-of-care diagnostic solutions to meet the needs of underserved populations. The company’s products are used for the detection of infectious diseases, such as HIV and HCV, as well as for the detection of drugs of abuse. OraSure’s products are sold in over 60 countries worldwide.
– Quidel Corp ($NASDAQ:QDEL)
Quidel Corporation is a molecular diagnostics company, providing diagnostic solutions that empower patients and physicians to make better healthcare decisions. The company has a market cap of $5.18 billion and a return on equity of 22.75%. Quidel’s products are used in a variety of settings, including hospitals, physician offices, and retail pharmacies. Quidel’s products are used to diagnose a wide range of conditions, including influenza, respiratory syncytial virus, and tuberculosis. Quidel also offers a variety of point-of-care tests, including tests for pregnancy, ovulation, and infectious diseases.
– Lucira Health Inc ($NASDAQ:LHDX)
Lucira Health Inc is a medical technology company that develops and commercializes molecular diagnostics products. The company’s products are designed to enable earlier and more accurate detection of infectious diseases. Lucira Health’s products include the Lucira COVID-19 All-In-One Test Kit, which is the first FDA-cleared molecular test for the self-collection and detection of COVID-19. The company has a market cap of $46.12 million and a return on equity of -13.64%.
Summary
Abbott Laboratories has recently increased its quarterly dividend by 7.8% to $0.55 per share, a positive sign for current and potential investors. This dividend increase demonstrates the company’s commitment to providing shareholders with a steady stream of income. Abbott’s strong financial position and solid dividend payout history are promising indicators that this dividend increase is likely to be sustained over time.
On the other hand, investors should remain cautious and consider any macroeconomic trends or other external factors that may lead to a decrease in Abbott’s profits and, in turn, could affect the ability to maintain dividends at this level. Ultimately, investments in Abbott Laboratories offer investors a reliable source of income with the potential for long-term growth.
